Hydrogen Gas Attenuates Toxic Metabolites and Oxidative Stress-Mediated Signaling to Inhibit Neurodegeneration and Enhance Memory in Alzheimer’s Disease Models.
Abdul-Nasir S, Chau CT, Nguyen TT, Bajgai J, Rahman MH, Hwang-Un K, You IS, Kim CS, Seo BA, Lee KJ · International journal of molecular sciences · 2025
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
The publication “Hydrogen Gas Attenuates Toxic Metabolites and Oxidative Stress-Mediated Signaling to Inhibit Neurodegeneration and Enhance Memory in Alzheimer’s Disease Models.” is organized in H2HUBB under the research focus molecular hydrogen alzheimer’s disease study 2025. The publication is cited as Abdul-Nasir S, Chau CT, Nguyen TT, Bajgai J, Rahman MH, Hwang-Un K, You IS, Kim CS, Seo BA, Lee KJ, International journal of molecular sciences, 2025. This animal study examined Hydrogen Gas Attenuates Toxic Metabolites and Oxidative Stress-Mediated Signaling to Inhibit Neurodegeneration and Enhance Memory in Alzheimer’s Disease Models. The abstract describes Mouse model; reported duration 60 days. The abstract reports: These results suggest that H therapy can mitigate toxic metabolites in the astrocytic urea cycle, thereby reducing neurodegeneration and memory loss in AD. This is an automated editorial draft based on the abstract and requires source review before publication.
Molecular hydrogen alzheimer’s disease study 2025 overview
Therefore, we investigated whether H treatment could reduce OS-induced neurodegeneration and memory loss. Animal research can identify biological effects and support future investigation, but it cannot by itself establish safety or effectiveness in humans.
Study design and hydrogen intervention
Publication type: Animal study. Evidence type: Preclinical animal evidence. Research model or population: Mouse model. Randomized: Yes. Blinding: Unknown. Control status: Unknown.
Delivery method: Other or not reported. Treatment duration: 60 days.
Reported findings and scientific interpretation
For this molecular hydrogen alzheimer’s disease study 2025, the study record reports the following: The abstract reports: These results suggest that H therapy can mitigate toxic metabolites in the astrocytic urea cycle, thereby reducing neurodegeneration and memory loss in AD.
These findings should be interpreted as one piece of evidence rather than as a stand-alone medical conclusion. Results can be influenced by the research model, study design, treatment protocol, sample size, outcome selection, statistical methods, and whether the findings have been independently reproduced.
How this research record was prepared
H2HUBB organizes bibliographic details, study design information, intervention data, outcomes, limitations, and safety notes from the available scientific source. Automated classification supports database organization, but it does not replace critical reading of the complete paper. Source identifiers, evidence labels, and delivery-method fields are retained so readers can verify the record and compare it with related publications. A missing field means the information was unavailable or not reported in the structured source; it should not be treated as a negative finding.
Limitations, safety, and original source
Limitations: Preclinical animal findings may not translate directly to human outcomes.
The intervention or follow-up period appears relatively short.
Safety: The abstract did not provide detailed safety or adverse-event information.
This H2HUBB page is an educational research record, not medical advice. Review the original scientific source for the complete methods and results. Continue exploring the H2HUBB Molecular Hydrogen Research Library to compare evidence types, delivery methods, and related topics.